COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

Start Date17 Dec 2025

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+4]

JPRN-jRCT2031230204

/ CompletedPhase 1IIT

TO-208 Clinical Pharmacology Study- Open-Label Study to Evaluate the Safety, Efficacy, and Plasma Concentrations of TO-208 in Patients Aged 2 Years and Older with Molluscum Contagiosum -

Start Date27 Jul 2023

Sponsor / Collaborator-

NCT05597098

/ RecruitingEarly Phase 1

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women: RESOLVE-SEX

Important differences exist between sexes in incidence, disease patterns and outcomes in coronary artery disease that is not well understood. It is likely that key differences in the underlying biological mechanism, in particular in inflammatory responses, play a part in underpinning these differences. Previous evidence demonstrates that healthy females appear to be more adept at resolving inflammation compared to healthy males. Since inflammation is thought to be a key initiating phenomenon in coronary artery disease the investigators will examine the differences in inflammatory resolution between the sexes in healthy volunteers.

Start Date12 Dec 2022

Sponsor / Collaborator

Queen Mary University of London

100 Clinical Results associated with Cantharidin

100 Translational Medicine associated with Cantharidin

100 Patents (Medical) associated with Cantharidin

1,105

Literatures (Medical) associated with Cantharidin

01 Apr 2026·BIOCHEMICAL PHARMACOLOGY

Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma

Article

Author: Wang, Yuehua ; Yan, Jia ; Chen, Jie ; Gou, Xianggang ; Wang, Ziyao ; Yuan, Henye ; Wang, Haisheng ; Zhou, Zhongzheng ; Yan, Wei

Cantharidin (CTD) has been traditionally used in Traditional Chinese Medicine (TCM) and exhibits pronounced antitumor activity, particularly in hepatocellular carcinoma (HCC). However, its preclinical translation has been substantially constrained by dose-limiting toxicity. Inspired by traditional Mylabris and Ginseng combinations, we conducted an investigation into the synergistic efficacy of CTD and Ginsenoside-Rg3 (Rg3), one of the most prevalent and bioactive ginsenosides, in combating HCC. We find that CTD/Rg3 co-treatment synergistically suppressed HCC cell proliferation, migration, and invasion. Mechanistically, an integrated multi-omics approach analyses illuminated the involvement of multi-target and multi-pathway mechanisms in CTD/Rg3 combination therapy for HCC. Function enrichment analyses reveal that targets of CTD/Rg3 were significantly associated with metabolic pathways and immune responses. Further screening identified AKR1D1, SLC16A4, and ALDH3B1 as potential drug targets. Subsequent correlation analysis with clinical data from liver cancer patients indicated that AKR1D1 and SLC16A4 were activated, whereas ALDH3B1 was inhibited, during CTD/Rg3 intervention in HCC progression. Molecular docking studies further demonstrated that both CTD and Rg3 bind with high affinity and stability to the active site of ALDH3B1, a molecule associated with immune microenvironment remodeling in HCC. Collectively, our findings demonstrate that CTD/Rg3 combination therapy exerts potent anti-HCC effects through multi-targeted mechanisms. By simultaneously modulating metabolic pathways and immune responses, this strategy represents a novel integrative approach for HCC treatment. These results not only elucidate the molecular basis of CTD/Rg3 efficacy but also provide robust preclinical support for its clinical translation in HCC management.

01 Apr 2026·JOURNAL OF INORGANIC BIOCHEMISTRY

Discovery, crystal structure, anticancer property of the first-row transition metal complexes of norcantharidin (NCTD) as potential inducer of mitochondrial damage

Article

Author: Liu, Li-Min ; Wen, Chang-Chun ; Wei, Hong-Zu ; Liu, Yan-Cheng ; Huang, Yue ; Huang, Yun-Hou ; Liu, Yuan ; Meng, Wei-Ying

Norcantharidin (NCTD) is a structurally modified derivative of cantharidin, which is an active component derived from traditional Chinese medicine (TCM) and exhibiting specific anticancer activity. In this work, four pH-sensitive complexes of NCTD, with cationic 2-aminopyridine (AP) as the counter ion, were successfully synthesized and structurally characterized. The crystal structures resolved by single crystal X-ray diffraction analysis demonstrated that they all formed in complexes with ionic type, 2AP[M(NCTD)₂], (M = Cu, Co, Ni and Mn), composed of the negative divalent six-coordinated species, [M(NCTD)₂]^2-, and two counter cations (AP). Our findings demonstrated that under slightly acidic conditions (pH = 6.6), the decomposition of 2AP[M(NCTD)₂] (M = Cu, Co, Ni, and Mn) led to the release of NCTD and metal ions, which subsequently triggered a Fenton-like reaction co-catalyzed by GSH. They exhibited stronger in vitro anticancer properties than NCTD against a series of typical cancer cell lines tested, with the IC₅₀ values in the range of 12.41-33.43 μM, in which 2AP[Cu(NCTD)₂], showed the best efficacy. In the most sensitive SK-OV-3 cells, 2AP[Cu(NCTD)₂], induced mitochondrial dysfunction by triggering the excessive accumulation of ROS within mitochondria, thereby activating the apoptotic pathway. Meanwhile, 2AP[Cu(NCTD)₂], could obviously arrest the cell cycle at Sub-G₁ phase in SK-OV-3 cells.

01 Feb 2026·SEMINARS IN ONCOLOGY

Nanoparticle-based approaches for doxorubicin delivery in hepatocellular carcinoma: Current strategies and emerging innovations

Review

Author: Negi, Hansi ; Al-Hetty, Hussein Riyadh Abdul Kareem ; Panigrahi, Rajashree ; Salih, Salah Abdulhadi ; RenukaJyothi, S ; Ahmed, Abdulrahman T ; Alkhathami, Ali G ; Hammady, Fathi Jihad ; Hussn, Ahmed ; Jassal, Pushkar

Globally, hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death, but HCC treatment with the chemotherapeutic doxorubicin is limited because of acquired drug resistance. In this review, we examined current knowledge on the specific molecular mechanisms of doxorubicin resistance in HCC, including overexpression of drug efflux (ABC family) transporters, aberrations of the drug target topoisomerase IIα (TOP2A), impairments in apoptosis (p53, FOXO3, Bcl-2 family members), oncogenic activation of pro-survival signaling pathways (NF-κB, PI3K/Akt, and MAPKs), instances of tumor heterogeneity with sirtuins, and cancer stem cells. Additionally, we investigate the role of non-coding RNAs, particularly microRNAs and long non-coding RNAs, in modulating sensitivity to and resistance to doxorubicin in HCC. In conclusion, nanomedicine will become crucial in overcoming the limitations of significant doxorubicin resistance in HCC, utilizing advanced mechanisms to modulate treatment with doxorubicin in this context. This review details various nanotechnology-based approaches to the delivery of doxorubicin, including passive targeting using the enhanced permeability and retention (EPR) effect, active targeting with specific ligands, and stimulus-responsive drug release in the tumor microenvironment (e.g., pH, redox potential). We focus on preclinical studies that utilized a variety of nanoparticle formulations for palliative care to patients with HCC, have investigated the use of liposomes, polymeric nanoparticles (e.g., PCL, chitosan), metallic particles (e.g., gold, silver, iron oxide), dendrimers, and metal-organic frameworks (MOFs), which have been loaded with doxorubicin or combined with other agents (e.g., cantharidin, berberine, isoginkgetin, ginger extract). The nanoparticle formulations enhanced drug delivery, increased drug accumulation per cell, reduced systemic toxicity, and overcame drug resistance mechanisms in HCC models.

106

News (Medical) associated with Cantharidin

09 Feb 2026

·www.biospace.com

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”). “We would like to congratulate our partner, Torii, on the launch of YCANTH in Japan for the treatment of molluscum. Torii’s achievement also represents an exciting milestone for Verrica, as we continue to execute on our long-term strategy of developing and commercializing YCANTH across multiple dermatologic indications around the world, as Verrica maintains ownership of global rights to YCANTH in all territories outside Japan,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “With few treatments currently available in Japan, the launch of YCANTH will enable access to a therapy which addresses this significant unmet need, and based on the strength of its safety and efficacy data in multiple Phase 3 studies, we believe YCANTH is poised to gain broad adoption for this indication over time. We wish Torii continued success in developing and now commercializing YCANTH in molluscum, and we look forward to our continued collaboration as we advance YCANTH for the treatment of common warts.” In September 2025, Verrica announced that Torii received approval from the Japanese Ministry of Health, Labour and Welfare (“MHLW”) for YCANTH ® (developed under the name TO-208) for the treatment of molluscum. Torii filed the New Drug Application for TO-208 in molluscum with MHLW in December 2024. Approval of YCANTH in Japan was based on positive top-line results from a confirmatory Phase 3 trial for the treatment of molluscum. The Phase 3 trial was conducted in Japan and was a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of TO-208 in comparison to placebo, when applied once every 21 days for up to four applications in patients with molluscum. The top-line results from the trial showed that the proportion of subjects achieving complete clearance of all treatable molluscum lesions at the completion of the confirmatory study, the primary endpoint of efficacy, was statistically significant versus placebo. TO-208 was well tolerated during the study. In July 2025, as part of its amended collaboration and license agreement with Torii, Verrica announced plans to initiate a manufacturing transfer to Torii for YCANTH applicators to be sold in Japan, which is expected to take several years. In the interim, Verrica will receive from Torii a transfer price for applicators manufactured by Verrica’s manufacturing partners. After the transfer of at least one component of the manufacturing process, Verrica will begin receiving royalties related to net sales in Japan of applicators manufactured by Torii and/or its manufacturing partners. About YCANTH ® (VP-102) YCANTH ® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information. About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH ® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH ® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH in Japan and the United States, and clinical development of YCANTH for the treatment of common warts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2024, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com

Phase 3Clinical ResultDrug ApprovalLicense out/in

09 Feb 2026

·www.shionogi.com

Shionogi Notes Torii Pharmaceutical’s Announcement on the Launch of YCANTH® topical solution 0.71% for the Treatment of Molluscum Contagiosum in Japan

OSAKA, Japan, February 9, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) announces today that its group company, Torii Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President and Chief Executive Officer: Nobumasa Kondo), has issued a press release announcing the launch in Japan of YCANTH® topical solution 0.71% for the Treatment of Molluscum Contagiosum. Below is the announcement released by Torii Pharmaceutical. Torii Pharmaceutical Co., Ltd. (Torii) is pleased to announce today the launch of YCANTH® topical solution 0.71% (cantharidin) for the treatment of molluscum contagiosum in Japan. This product received manufacturing and marketing approval in Japan for the indication of molluscum contagiosum, a common pediatric skin infection, on September 19, 2025, and has been listed on the Japanese National Health Insurance (NHI) drug price list on November 12, 2025. YCANTH® topical solution 0.71% is a topical solution for the treatment of molluscum contagiosum in patients (≥2 years old) that use cantharidin as its active ingredient. While the exact mechanism of action of YCANTH® is not fully understood, it is thought that when applied to the affected area, it activates neutral serine proteases, weakening epidermal desmosomes of the epidermis and breaks down the epidermal structure, and leading to the formation of intraepidermal blisters at the application site. The formation of these blisters causes the affected skin to peel off. The resulting peeling of the skin is believed to remove the virus-infected tissue, thereby providing a therapeutic effect. In the Phase 3 clinical program of YCANTH® topical solution 0.71% in patients with molluscum contagiosum (≥2 years old) in Japan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety of YCANTH® topical solution 0.71% was confirmed and there were no observed issues of tolerability for the application. Torii expects YCANTH® topical solution 0.71% to be a new option for the treatment of molluscum contagiosum patients (≥2 years old) in Japan. In the United States, Verrica Pharmaceuticals Inc. (Verrica) received approval for YCANTH® from the U.S. Food and Drug Administration in July 2023 for the topical treatment of molluscum contagiosum in adult and pediatric patients (≥2 years old) and launched YCANTH® in the US in August 2023. ＜YCANTH® topical solution 0.71% Information＞ Product name YCANTH® topical solution 0.71% Generic Name Cantharidin Indications Molluscum Contagiosum Dosage and administration For adults and pediatric patients (≥2 years old), apply an appropriate amount of solution to the affected area once every 3 weeks during treatment. 16 to 24 hours after application, washing affected area with soap. Package Glass Ampoule Applicator：0.45mL×5 （One braking tool attached） NHI Drug Price ¥14,995.60（0.71% 0.45mL） Approval Date September 19, 2025 NHI Pricing Date November 12, 2025 Launch Date February 9, 2026 Distributor Torii Pharmaceutical Co., Ltd. Import source Verrica Pharmaceuticals Inc. ABOUT Molluscum Contagiosum Molluscum contagiosum is a highly contagious viral skin infection caused by the molluscum contagiosum virus, a member of the poxviridae family, commonly known as "water warts." It primarily affects children and is characterized by small, shiny papules (1–4 mm in diameter) on the trunk and extremities. ABOUT Common Warts Common warts (Verruca vulgaris) are a common dermatologic disease caused by infection with the human papillomavirus (HPV), commonly known as “warts”. They typically appear keratinized, raised bumps (several mm to 1 cm) on the hands and feet. For Further Information, Contact: SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html

Phase 3Drug ApprovalClinical Result

08 Jan 2026

·www.globenewswire.com

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – Jan. 07, 2026 -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. “The dosing of the first patient in the global Phase 3 program in common warts represents an important clinical milestone for our label expansion strategy of YCANTH,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “The clinically meaningful activity observed for the primary endpoint of complete clearance in the Phase 2 COVE-1 study provides strong evidence that YCANTH has the potential to become the first therapy ever approved in both the United States and Japan for the treatment of common warts – a condition that impacts over 22 million people in the U.S. alone. Having retained full commercial rights for all potential YCANTH indications outside of Japan, common warts represents a substantial commercial and licensing opportunity for our company. Coupled with our recently completed $50 million financing and repayment of our debt facility with OrbiMed, this significant clinical milestone is another key step towards the expansion of the YCANTH franchise and the future growth of Verrica.” The initiation of the global Phase 3 program in common warts is based upon positive results from the Phase 2 COVE-1 clinical trial that evaluated YCANTH (VP-102) for the treatment of common warts. COVE-1 was an open label clinical trial that evaluated the safety and efficacy of VP-102 in two cohorts of subjects with up to six warts. The primary efficacy analysis was conducted at Day 84 with an additional period of follow-up through Day 147. Topline analysis included data from the assessment of warts at study visits over 12 weeks. Results showed that 51% of subjects (18 of 35) treated with VP-102 in Cohort 2 achieved complete clearance of all treatable warts at Day 84. Adverse events were primarily expected local cutaneous reactions with no SAEs observed. Torii will split the costs of the global Phase 3 program with Verrica on a 50/50 basis and will fund the first $40 million of trial costs, representing approximately 90% of the current trial budget, with Verrica’s portion expected to be paid out of future milestones/royalties for YCANTH in Japan. With a prevalence of approximately 22 million patients in the U.S. alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology, which Verrica believes could represent a multibillion-dollar commercial opportunity. In the United States, approximately 50% of the patients who seek treatment for common warts are children. If YCANTH is successfully developed, approved and commercialized for the treatment of common warts, Verrica anticipates a high degree of call point overlap and marketing synergies with its promotion of YCANTH for the treatment of molluscum. Verrica further believes that the common wart patient opportunity in the European Union is comparable to that in the United States. YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultLicense out/inDrug Approval

100 Deals associated with Cantharidin

External Link

KEGG	Wiki	ATC	Drug Bank
D11745	Cantharidin	D11AF	DB12328

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Molluscum Contagiosum	United States	Verrica Pharmaceuticals, Inc.	21 Jul 2023
Condylomata Acuminata	China	Hainan Huiyuantang Pharmaceutical Co Ltd	10 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plantar wart	Phase 3	United States	Verrica Pharmaceuticals, Inc.	17 Dec 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2025	Phase 3	Molluscum Contagiosum	303	TO-208	wwphkdtzyf(uzyehnhpvm) = xiacwacabl diqvavcjre (qbwsasnjgi ) View more	Positive	07 Mar 2025
				Placebo	wwphkdtzyf(uzyehnhpvm) = wbhitcpfez diqvavcjre (qbwsasnjgi ) View more
GlobeNewswire Manual	Phase 3	Molluscum Contagiosum	-	TO-208	mpkmvmegut(qdejbgmmle) = statistically significant versus placebo tmljehpieb (xmmkaotbqa )	Positive	15 Dec 2023
				Placebo
NCT03377803 \| NCT03377790 (FDA) Manual	Phase 3	Molluscum Contagiosum	528	YCANTH (Trial 1)	wdecjsuayl(mkmogeblex) = smmbmczmhu brmzenctyi (fbgfntnggc ) View more	Positive	21 Jul 2023
				Vehicle (Trial 1)	wdecjsuayl(mkmogeblex) = sayzrfmtha brmzenctyi (fbgfntnggc ) View more
NCT03377803 (CAMP-2, CTgov)	Phase 3	Molluscum Contagiosum	262	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	krcemqxnja = dltxzrziuj stzijrcugh (dgflxjdcrp, nmqjsfbyvz - hbazvficbx) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	krcemqxnja = nnpigpexlg stzijrcugh (dgflxjdcrp, frsystcjap - awsrcawdqt) View more
NCT03377790 (CAMP-1, CTgov)	Phase 3	Molluscum Contagiosum	266	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	fojveoscpc = ulwuqaoako qimgxbvhnt (dtpmfwrhdd, mvatrvfpdw - ehdyylduew) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	fojveoscpc = onhjncvpwm qimgxbvhnt (dtpmfwrhdd, dtdmmrfvvu - wiclwtuqet) View more
NCT03981822 (Pubmed \| Am J Clin Dermatol) Manual	Phase 2	Condylomata Acuminata	-	VP-102	pffpsazjzo(wgdkbfaojw) = kcuamsabsf zzkxxmkdzr (vewawnzbbc ) View more	Positive	01 Nov 2021
				Placebo	pffpsazjzo(wgdkbfaojw) = gbavjrotgd zzkxxmkdzr (vewawnzbbc ) View more
NCT03487549 (COVE-1, Pubmed) Manual	Phase 2	Warts	56	VP-102 (Cohort 1)	ggkadjsvvp(wtmqgbthuy) = talqmfrjaf mabhwkdodi (mtxupzumhk )	Positive	01 Oct 2021
				VP-102 (Cohort 2)	ggkadjsvvp(wtmqgbthuy) = ozetmoowuw mabhwkdodi (mtxupzumhk )
NCT03981822 (CARE-1, CTgov)	Phase 2	Condylomata Acuminata	105	VP-102 (Part B Pooled With Part A: VP-102 6-hour)	gyjwscnacx: P-Value = 0.0048 View more	-	22 Sep 2021
				Placebo (Part B Pooled With Part A: Placebo 6-hour)
NCT03487549 (COVE-1, CTgov)	Phase 2	Warts	56	VP-102 (Cohort 1)	budhxehgnd = ygbqndwuwu frxzguaufm (ivzfxmqoet, nknspwzlgk - kwwzvxyxde) View more	-	01 Sep 2021
				VP-102 (VP-102 - Cohort 2)	fdlpcpsbcz = jwwbowwckc avelursixt (hxcmjylihp, vnpcxhjqup - yzubuaapxs) View more
NCT03186378 (CTgov)	Phase 2	Molluscum Contagiosum	33	VP-102 with applicator (Exposure Group)	rktqvrwvae = wysxmzgysm pcffzvigtd (pnmfqrqajw, rplvnrqrhd - ktqxcfcnqt) View more	-	09 Aug 2021
				VP-102 with applicator (Standard Group)	rktqvrwvae = dhxrrdtxgk pcffzvigtd (pnmfqrqajw, aluwnkkcvx - wmgmdyjxks) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cantharidin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation